## REMARKS

With entry of this amendment, Claims 1, 3-5 and 11 are pending. No new matter has been added.

**Declaration under 37 C.F.R. §1.132**

As described in the attached Declaration, the inventors preformed cytotoxicity studies comparing glycyrrhizin, glycyrrhetinic acid mono glucuronide and glycyrrhetinic acid. The minimum cytotoxic concentration of glycyrrhizin was determined to be approximately 2,000 mg/ml, whereas the minimum cytotoxic concentration of glycyrrhetinic acid mono glucuronide was determined to be 250 mg/ml/ These results suggest that for bovine mammary epithelial cells, glycyrrhetinic acid mono glucuronide is 8 fold more toxic than glycyrrhizin. The data supplied by the Declaration of the inventors submitted in the parent application indicates that glycyrrhetinic acid is twenty times more toxic to cow mammae cells than glycyrrhizin. Glycyrrhetinic acid or its derivatives such as glycyrrhetinic acid mono glucoronide would therefore not be suitable for use in the present invention.

No new matter has been added by these remarks. In light of the remarks, Applicants are of the opinion that the application is now in condition for allowance. Such action is respectfully requested. If the Examiner believes any informalities remain in the application which may be corrected by Examiner's Amendment, or there are any other issues which can be resolved by telephone interview, a telephone call to the undersigned attorney at (404) 815-6500 is respectfully solicited.

Respectfully submitted,

KILPATRICK STOCKTON, LLP



By: Janina A. Malone
Reg. No.: 47,768

KILPATRICK STOCKTON LLP
1100 Peachtree Street, Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-6500
Docket: 44471/288235